Literature DB >> 25751229

Single Hepatocellular Carcinoma: Preoperative MR Imaging to Predict Early Recurrence after Curative Resection.

Chansik An1, Dong Wook Kim1, Young-Nyun Park1, Yong Eun Chung1, Hyungjin Rhee1, Myeong-Jin Kim1.   

Abstract

PURPOSE: To identify magnetic resonance (MR) imaging features that enable prediction of early recurrence (<2 years) after curative resection of hepatocellular carcinoma (HCC) and to derive a preoperative prediction model.
MATERIALS AND METHODS: This retrospective study was approved by the institutional review board. The requirement to obtain written informed consent was waived. A total of 268 patients who underwent hepatic resection for a single HCC from January 2008 to August 2011 were divided into two cohorts: a training cohort, which was used to derive a prediction model (n = 187), and a validation cohort (n = 81). All MR images from the training cohort were reviewed by two radiologists. A prediction model was constructed by using MR imaging features that were independently associated with early recurrence with use of multiple logistic regression analysis. The performance of the prediction model in the validation cohort was evaluated with respect to discrimination (ie, whether the relative ranking of individual predictions of subsequent early recurrence is in the correct order).
RESULTS: In the training cohort, four MR imaging features were independently associated with early recurrence: rim enhancement (odds ratio [OR] = 3.83; 95% confidence interval [CI]: 1.39, 10.52), peritumoral parenchymal enhancement in the arterial phase (OR = 2.64; 95% CI: 1.27, 5.46), satellite nodule (OR = 4.07; 95% CI: 1.09, 15.21), and tumor size (OR = 1.66; 95% CI: 1.31, 2.09). A prediction model derived from these variables showed an area under the receiver operating characteristic curve (AUC) of 0.788 in the prediction of the risk of early recurrence in the training cohort. When applied to the validation cohort, this model showed good discrimination (AUC, 0.783).
CONCLUSION: The prediction model derived from rim enhancement, peritumoral parenchymal enhancement, satellite nodule, and tumor size can be used preoperatively to estimate the risk of early recurrence after resection of a single HCC. (©) RSNA, 2015 Online supplemental material is available for this article.

Entities:  

Mesh:

Year:  2015        PMID: 25751229     DOI: 10.1148/radiol.15142394

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  42 in total

Review 1.  Current status of imaging biomarkers predicting the biological nature of hepatocellular carcinoma.

Authors:  Norihide Yoneda; Osamu Matsui; Satoshi Kobayashi; Azusa Kitao; Kazuto Kozaka; Dai Inoue; Kotaro Yoshida; Tetsuya Minami; Wataru Koda; Toshifumi Gabata
Journal:  Jpn J Radiol       Date:  2019-02-02       Impact factor: 2.374

2.  Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma Using Quantitative Image Analysis.

Authors:  Jian Zheng; Jayasree Chakraborty; William C Chapman; Scott Gerst; Mithat Gonen; Linda M Pak; William R Jarnagin; Ronald P DeMatteo; Richard K G Do; Amber L Simpson
Journal:  J Am Coll Surg       Date:  2017-09-21       Impact factor: 6.113

3.  Gadoxetic acid-enhanced MRI radiomics signature: prediction of clinical outcome in hepatocellular carcinoma after surgical resection.

Authors:  Zhen Zhang; Jie Chen; Hanyu Jiang; Yi Wei; Xin Zhang; Likun Cao; Ting Duan; Zheng Ye; Shan Yao; Xuelin Pan; Bin Song
Journal:  Ann Transl Med       Date:  2020-07

4.  Magnetic resonance imaging with gadoxetic acid for local tumour progression after radiofrequency ablation in patients with hepatocellular carcinoma.

Authors:  Tae Wook Kang; Hyunchul Rhim; Jisun Lee; Kyoung Doo Song; Min Woo Lee; Young-Sun Kim; Hyo Keun Lim; Kyung Mi Jang; Seong Hyun Kim; Geum-Youn Gwak; Sin-Ho Jung
Journal:  Eur Radiol       Date:  2016-01-08       Impact factor: 5.315

5.  Identification of Imaging Predictors Discriminating Different Primary Liver Tumours in Patients with Chronic Liver Disease on Gadoxetic Acid-enhanced MRI: a Classification Tree Analysis.

Authors:  Hyun Jeong Park; Kyung Mi Jang; Tae Wook Kang; Kyoung Doo Song; Seong Hyun Kim; Young Kon Kim; Dong Ik Cha; Joungyoun Kim; Juna Goo
Journal:  Eur Radiol       Date:  2015-12-03       Impact factor: 5.315

6.  Gadoxetic acid-enhanced magnetic resonance imaging characteristics of hepatocellular carcinoma occurring in liver transplants.

Authors:  Mimi Kim; Tae Wook Kang; Woo Kyoung Jeong; Young Kon Kim; Seong Hyun Kim; Jong Man Kim; Dong Hyun Sinn; Min-Ji Kim; Sin-Ho Jung
Journal:  Eur Radiol       Date:  2016-12-12       Impact factor: 5.315

7.  Diffusion kurtosis imaging (DKI) of hepatocellular carcinoma: correlation with microvascular invasion and histologic grade.

Authors:  Likun Cao; Jie Chen; Ting Duan; Min Wang; Hanyu Jiang; Yi Wei; Chunchao Xia; Xiaoyue Zhou; Xu Yan; Bin Song
Journal:  Quant Imaging Med Surg       Date:  2019-04

8.  Preoperative MRI features and clinical laboratory indicators for predicting the early therapeutic response of hepatocellular carcinoma to transcatheter arterial chemoembolization combined with High-intensity focused ultrasound treatment.

Authors:  Haiping Zhang; Xiaojing He; Jiayi Yu; Wenlong Song; Xinjie Liu; Yangyang Liu; Jun Zhou; Dajing Guo
Journal:  Br J Radiol       Date:  2019-06-05       Impact factor: 3.039

9.  Hepatocellular Carcinoma with Irregular Rim-Like Arterial Phase Hyperenhancement: More Aggressive Pathologic Features.

Authors:  Hyungjin Rhee; Chansik An; Hye-Young Kim; Jeong Eun Yoo; Young Nyun Park; Myeong-Jin Kim
Journal:  Liver Cancer       Date:  2018-05-15       Impact factor: 11.740

10.  A nomogram based on bi-regional radiomics features from multimodal magnetic resonance imaging for preoperative prediction of microvascular invasion in hepatocellular carcinoma.

Authors:  Rui Zhang; Lei Xu; Xue Wen; Jiahui Zhang; Pengfei Yang; Lixia Zhang; Xing Xue; Xiaoli Wang; Qiang Huang; Chuangen Guo; Yanjun Shi; Tianye Niu; Feng Chen
Journal:  Quant Imaging Med Surg       Date:  2019-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.